Philadelphia positive chronic myeloid leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:25:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Philadelphia positive chronic myeloid leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Bioavailability of Nilotinib in Healthy Individuals with Chronic Myelogenous Leukemia (CML) https://clinicaltrials.eu/trial/study-on-the-bioavailability-of-nilotinib-in-healthy-individuals-with-chronic-myelogenous-leukemia-cml/ Wed, 29 Apr 2026 15:05:25 +0000 https://clinicaltrials.eu/trial/study-on-the-bioavailability-of-nilotinib-in-healthy-individuals-with-chronic-myelogenous-leukemia-cml/ This clinical trial is focused on studying the bioavailability of a medication called Nilotinib, which is used to treat a type of blood cancer known as Chronic Myelogenous Leukemia (CML). The study involves comparing different forms of Nilotinib capsules to understand how the body absorbs the medication. The trial is designed to explore the differences in how the medication is processed in the body when taken in different forms.

Participants in the study will be healthy individuals who will receive a single dose of Nilotinib in a controlled setting. The study will follow a specific plan where participants will take the medication in different sequences and periods. This approach helps researchers understand the medication’s absorption and processing in the body. The study will also include a comparison with a placebo to ensure accurate results.

The main goal of the study is to assess the safety and effectiveness of Nilotinib by monitoring participants for any side effects and measuring how the medication is absorbed. This information will help improve the understanding of Nilotinib and its use in treating Chronic Myelogenous Leukemia. Participants will be closely monitored throughout the study to ensure their safety and well-being.

]]> Study on Ponatinib for Achieving Treatment-Free Remission in Patients with Chronic Myeloid Leukemia https://clinicaltrials.eu/trial/study-on-ponatinib-for-achieving-treatment-free-remission-in-patients-with-chronic-myeloid-leukemia/ Wed, 29 Apr 2026 15:02:00 +0000 https://clinicaltrials.eu/trial/study-on-ponatinib-for-achieving-treatment-free-remission-in-patients-with-chronic-myeloid-leukemia/ This clinical trial is focused on studying a type of blood cancer called chronic myeloid leukemia (CML), specifically in its chronic phase. The treatment being tested is a medication called Ponatinib, which is taken as a film-coated tablet. Ponatinib is a type of drug known as a tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to assess patients who have achieved a specific level of response, known as MR4, after two years of treatment with Ponatinib. MR4 is a term used to describe a deep molecular response, indicating a very low level of cancer cells in the body. The study will follow participants over a period of 24 months to monitor their response to the treatment. During this time, researchers will evaluate the molecular status of the disease, the safety and tolerability of Ponatinib, and any side effects that may occur. Additionally, the study will look at the quality of life of participants while on the treatment.

Throughout the study, researchers will also identify factors that may be associated with achieving MR4 or better, such as risk scores and the duration of previous treatments. The study aims to provide insights into the potential for treatment-free remission, where patients may be able to stop treatment while maintaining their response. Overall survival and progression-free survival will also be evaluated to understand the long-term benefits of Ponatinib therapy.

]]> Study on the Dose and Safety of Asciminib in Children with Chronic Myeloid Leukemia https://clinicaltrials.eu/trial/study-on-the-dose-and-safety-of-asciminib-in-children-with-chronic-myeloid-leukemia/ Wed, 29 Apr 2026 14:29:00 +0000 https://clinicaltrials.eu/trial/study-on-the-dose-and-safety-of-asciminib-in-children-with-chronic-myeloid-leukemia/ This clinical trial is focused on studying a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) in children. This condition is a form of leukemia, which is a cancer of the blood and bone marrow. The study is testing a medication called Asciminib, also known by its code name ABL001. Asciminib is taken as a film-coated tablet and is designed to be used by patients who have already been treated with other medications known as tyrosine kinase inhibitors.

The purpose of the study is to determine the appropriate dose and safety of Asciminib in children with this type of leukemia. The study will involve giving the medication to pediatric patients and monitoring how their bodies process the drug. This will help researchers understand how the drug behaves in children compared to adults. The study will also look at the safety of the medication by observing any side effects that may occur during the treatment period.

Participants in the study will take Asciminib orally, and the study will track their response to the medication over time. The researchers will collect information on how well the drug is tolerated and its effects on the leukemia. The study aims to find a dose that provides similar drug exposure in children as seen in adults, ensuring the treatment is both effective and safe for younger patients. The study will also gather feedback on how acceptable and palatable the medication is for the children taking it.

]]>